Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.80 |
| ▸ | INSR | P06213 | 3/20 | 0.80 |
| ▸ | GSK3B | P49841 | 5/20 | 0.77 |
| ▸ | GSK3A | P49840 | 4/20 | 0.77 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | NAT1 | P18440 | 1/20 | 0.61 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277839 | 1.00 | IGF1R (0.80) | IGF1RINSRGSK3BGSK3ASIRT2 | |
| SCHEMBL5124788 | 1.00 | IGF1R (0.80) | IGF1RINSRGSK3BGSK3ASIRT2 | |
| SCHEMBL3360967 | 0.87 | TTR (0.82) | IGF1RINSRGSK3BGSK3APIK3CG | |
| SCHEMBL30657767 | 0.87 | TTR (0.82) | IGF1RINSRGSK3BGSK3APIK3CG | |
| SCHEMBL12989661 | 0.87 | TTR (0.82) | IGF1RINSRGSK3BGSK3APIK3CG | |
| SCHEMBL3896737 | 0.87 | HSPD1 (0.61) | IGF1RINSRGSK3BGSK3ASIRT2 | |
| SCHEMBL3896735 | 0.87 | HSPD1 (0.61) | IGF1RINSRGSK3BGSK3ASIRT2 | |
| SCHEMBL3360964 | 0.87 | TTR (0.82) | IGF1RINSRGSK3BGSK3APIK3CG | |
| SCHEMBL3904132 | 0.86 | IGF1R (0.72) | IGF1RINSRGSK3BGSK3ASIRT2 | |
| SCHEMBL6089724 | 0.86 | IGF1R (0.72) | IGF1RINSRGSK3BGSK3ASIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051445-A1 | 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways | NATIONAL INSTITUTE OF IMMUNOLOGY. | 2008-02-28 | — | — | US | disclosed |
| EP-1834642-A2 | 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways | National Institute of Immunology (IN) | 2007-09-19 | — | — | EP | disclosed |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | disclosed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | IGF1R 2948/4885INSR 1443/4885GSK3B 4757/4885 |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | IGF1R 2948/4885INSR 1443/4885GSK3B 4757/4885 |
| US-20080051445-A1 | 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways | FASN, FADS2, TECR | IGF1R 3557/4885INSR 2530/4885GSK3B 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.